EU Announces Anti-trust Probe into a Cephalon – Teva Deal Concerning Generic Provigil

April 29, 2011


The European Union’s antitrust watchdog said Thursday it had launched an ex officio probe of U.S. pharmaceutical giant Cephalon Inc.’s alleged attempt to pay Teva Pharmaceutical Industries Ltd. to keep Modafinil, a generic version of narcolepsy drug Provigil off the market.

Provigil is a stay-awake drug that is used to treat the sleeping sickness narcolepsy and also became popular among night-workers such as truckers and has been tested for military use. It enables users to stay awake for days. (I couldn’t find any information as to whether it works during lectures).

The probe concerns a deal struck between the Cephalon and Teva that “may have had the object or effect of hindering the entry of generic Modafinil” into the European Economic Area.

The case arises from a December 2005 deal to settle patent infringement disputes in Britain and the United States, which saw Teva undertake not to sell its generic Modafinil products in the European single market before October 2012. The probe does not indicate “a definitive finding of an infringement. There is no set deadline for an outcome. Various side deals are also under investigation by US antitrust authorities.

Generic drugs are far cheaper, typicaly costing about 40 percent less than the first, patented drug. The EU has been probing the sector repeatedly since a report showed that the number of new drugs reaching the market annually had dropped by over a third since 2000 and that people were being deprived of innovative, affordable and safe medicine.

What is clear from this probe is that whilst supplementary protection certificates (SPC) are available in Europe to prolong patent protection for the first patent for a new drug, the European Union sees generic drug availability as in the public interest. The law tries to strike a balance and cartels that upset this delicate balance are unacceptable.


Minyan at INTA

April 28, 2011

Rabbi Avram Bilenski, otherwise known as the Frisco Kid,  is looking for one or two more adult Jewish males to complete a minyan at INTA; thereby facilitating communal daily prayers. This is particularly important this year as a couple of members of the Tribe who will be participating in the conference are saying kaddish for parents.

Contact me, mfactor@israel-patents.co.il if you are eligible and interested in joining us.

Wishing all participants at INTA, whatever their faith, a spiritual experience.

BTW – Wasn’t sure how to tag this post. In the end went for Jewish, gene patents, and trademarks.


Happy World IP Day

April 26, 2011

For any readers that were too busy celebrating Pesach or Easter, preparing for the Royal Wedding or otherwise too busy to notice, it is World IP Day today.

We take the opportunity to wish the world, IP Professionals, patentees, branding personnel and brand owners, authors and designers and the secretive lot that prefer trade secrets a hearty Mazel Tov.


Carbon Virgin Trademark Upheld in UK

April 22, 2011

The UK High Court has upheld a hearing officer’s decision rejecting an opposition filed by Virgin Enterprises Limited (VEL) under sections 5(2)(b) (likelihood of confusion) and 5(3) (unfair advantage) of the Trade Marks Act 1994,thereby allowing the word mark CARBON VIRGIN to be registered as a trade mark in class 35 for services including advertising, opinion polling and data processing.

The opposition was based on Virgin Enterprises Limited ‘s registrations of VIRGIN and other marks including the word “Virgin”. Norris J confirmed that appeals against a hearing officer’s decision were by way of review rather than rehearing (applying Reef TM [2003] RPC 5). Among other things, he upheld the finding that, while there was a reasonable level of visual and phonetic similarity between the marks, the word “Virgin” had a subtly different meaning in each mark, resulting in different concepts being created in the mind of the average consumer looking at the respective marks as a whole.

Case: Virgin Enterprises Ltd v Casey [2011] EWHC 1036 (Ch), 20 April 2011.

Despite noting that Richard Branson has attracted headlines for reducing carbon emissions, we approve of this decision, which contrasts nicely to the Israel Patent Office upholding a similar opposition from Virgin Enterprises against ‘Virgin Candles’ for candles made from olive oil. See http://blog.ipfactor.co.il/2007/11/10/david-loses-virgin-to-goliath/


Gaultier’s Perfume Bottle Registered as trademark in Japan

April 22, 2011

According to the Mainichi Daily News, the Japanese Intellectual Property High Court has overturned a 2010 Japan Patent Office Decision that refused to allow Gaultier’s distinctive female torso shaped bottle to be registered as a trademark.

For more details see http://mdn.mainichi.jp/arts/news/20110422p2g00m0et057000c.html

In Israel, the Israel Patent Office holds that bottle shapes can be registered as designs but not as trademarks. As someone critical of that decision, see: 3d-trademark-application-for-tahini-container-rejected/, I am pleased to see that the Japanese Court see’s things my way.

We note that the bottle has been in use for 15 years, so in Israel, a design registration would run out after this period. In such circumstances I think that trademark protection for truly distinctive containers, is appropriate.


Israel Patent Office Closed for Pesach

April 18, 2011

The Israel Patent Office is closed for Pesach. It will reopen on 29th April 2011. All deadlines in the interim are postponed until it reopens.

Israeli applicants wishing to file a PCT application with the Israel Patent Office after Pesach, claiming priority from a US provisional application, with a due date whilst the Israel Patent Office is closed should be aware that in such circumstances, the USPTO will not recognize priority from the provisional application.

In such circumstances, it is advisable to file in the US under the Paris Convention or to file the PCT in Geneva within 12 months of priority.

Wishing all our readers a Happy Pesach or Easter as applicable.


Is Night-time Electric Illumination for a Water Fountain Copyright Protectable?

April 17, 2011

Nathan Gavish is a landscape architect who specializes in illumination. On walking through Tel Aviv’s Gan Yehoshua park, he had an idea to illuminate the fountain for night-time enjoyment of passersby.

According to Gavish, on 9th March 2008, he set up a meeting with Mr Ronen, the CEO of the Park, and showed him a presentation detailing his idea which, in his words, included angles of illumination, specific alternating colours of magenta, blue and green, and specific intensities.

The meeting finished with Mr Ronen requesting a quotation.

The quotation related to costs for static and for flashing lights and included a section for the work in design and optimization of the illumination scheme. Mr Ronen didn’t bother to acknowledge the quotation and didn’t return Mr Gavish’s calls.

Some months later, on 14 October 2010, Mr Gavish crossed the park once more, and was shocked to see the fountain illuminated in accordance with his creation. He claimed moral rights and copyrights and requested NIS 80,000. When this money wasn’t forthcoming, he sued for NIS 100,000 statutory damages without proof of damage.

Judge Dr Shaul Avinor rejected the charges, ruling that the quotation, which included different options and was laconic, could not create copyright in the idea. Indeed there is no copyright in the idea. He went on to rule that illumination schemes are known and not copyright protectable. A different illumination specialist, Mr Teichmann, implemented the illumination. Even if Gavish had thought of illuminating the fountain, this did not create copyright in what was simply an idea.

COMMENT

It appears that the Judge, Dr Shaul Avinor is a Magistrate Court Judge in Herzliya. Under Israel Law, copyright cases should be heard by the District Court as the Court of First Instance. Avinor did not have Judicial Competence to rule on the case, and should not have heard it. Presumably neither side complained and so the issue is moot.

Judge Avinor is of the opinion that use of regular objects for the purpose intended, specifically outdoor lighting solutions does not have the creativity required for copyright protection.

In copyright for works of art, originality is required, but in contradistinction to Judge Avinor’s ruling, in Israeli Law there is no requirement for non-obviousness. In the US, a design patent does require aesthetic non-obviousness and interestingly, in re Hubry (153 USPQ 61 (CCPA 1967) the US Court accepted that a water fountain patent was acceptable for registration as a design patent, accepting thereby, both novelty and inventiveness in the transient nature of the cascading water. 

It is the appearance of the fountain under illumination that is copyright protectable, not the combination of lighting elements. conventional Sculptures may be created from stone or cast iron. It is not the choise of material or technique that is copyright protected, but the end result. As the present case relates to a one-off illumination project, not intended for mass production, there is no need under Israel Law for Gavish to have filed a design registration. I disagree with the judge, and believe that fountain illuminations can be considered as works of art, thereby being protectable by copyright.

Furthermore, I can quite understand why an artist who optimizes a design would show a simulation but not include the details in a design quotation so as to make it difficult for the potential customer to go elsewhere.

Not having been present in court, I cannot comment on whether the plaintiff presented sufficient evidence to show what his design was and whether the illumination put up was identical or not. However,  it seems to me that were the plaintiff to be able to produce a dated computer presentation of his illumination concept that could be authenticated as predating the order from the parks or from the Tel Aviv Municipality, I think this should be considered copyright infringement.

I don’t find the ruminations of the learned judge regarding TRIPS, his reference to Interlego  – which looked into whether Lego bricks could be considered copyright protected once the design rights expired, and his reference to the Premier League decision – which considers whether copyright resides in computer generated match fixtures, the least bit relevant.

I was also unimpressed with Ronen arguing that the Park was not the correct plaintiff, but that the Tel Aviv Municipality was.

The moral right to be credited as the artist of an illumination project is interesting. Presumably the fountain creator also has moral rights and could complain that illumination changes the appearance of the fountain. 

T.A. 13440-2-08 Ayalon Natan Gavish vs. Ganei Yehoshua LTD (Magistrate’s Court, Shaul Avinor) 12 April 2011. 


Israeli author files sues Google Books for copyright infringement

April 14, 2011

Yonatan Brauner, an author of the Hebrew book מה שרואים משם “Things you see from there” has filed suite in the Jerusalem District Court, claiming that the Google Book project, which makes millions of books publicly available for download, infringes on authors’ copyrights.
The Israeli daily newspaper Globes has reported that Brauner has asked the court to recognize the filing as a class-action lawsuit.
According to the Statement of Case, over 15 million books from more than 100 countries in 400 languages have been scanned and stored. These include thousands of books in Hebrew that were published in Israel and are protected by Israeli copyright law.
The Israel case follows a ruling issued last month by a New York federal judge, overturning a November 2008 agreement between several groups representing American authors and publishers and Google, on behalf of its Google Books initiative.

Never read the book myself…


Conference on Intellectual Property in Jewish Law

April 14, 2011

         

 

Are Delighted to Invite you to Participate in a

Conference on Intellectual Property in Jewish Law

JMB, Factor & Co. and Yad HaRav Herzogare delighted to invite you to a full day Conference on IP in Jewish Law, to be held on Sunday 26, June 2011 (24 Sivan 5771)

at the Yeshurun Center, 44 King George Street, Jerusalem.

TENTATIVE PROGRAM

Words of Welcome

Rabbi Prof. Abraham Sternberg 

My Grandfather Rabbi Yitzchak Issac Herzog’s Legacy

MK Isaac Herzog

The Halachic Basis of Intellectual Property in Jewish Law

Rabbi and Rabbinic Court Judge Zalman Nechemia Goldberg and

Former President of Supreme Rabbinic Court Rabbi Judge Shlomo Dzaichowski

Jurisprudence – IP in Jewish Law

Prof. Yechiel Kaplan, Haifa University

Bans and Approvals for Books – A Rabbinic Approach to Balancing Between Author and Publisher’s Rights and the Common Good

Rabbi Prof. Nahum Rakover, former Deputy Attorney General of the State of Israel and Director Jewish Legal Heritage Center

Halachic Obligation on the Individual to Recognize Secular IP Laws

Rabbi Yisrael Rosen, Director, The Zomet Institute

Historical Development of IP in Jewish Law

Rabbi Prof. Gershon Bacon, Bar-Ilan University 

An Overview of Recent Patent, Trademark and Copyright Issues of Interest to Jewish Law

Adv. Aharon Factor and Dr. Michael Factor, JMB, Factor & Co. 

The Influence of Secular Law on IP in Halacha

Prof. David Nimmer, UCLA

Copyright in Jewish Law from Maimonides to Microsoft

Prof. Neil Netanel, UCLA

Trade Secrets in Jewish Law

Prof. Jeremy Phillips, Center for Intellectual Property, QMW, University of London

COMPARATIVE APPROACH FROM OTHER MONETHEISTIC RELIGIONS

IP in Islamic Law

Prof. Amir Khoury, Tel Aviv University

IP in Christian Law

Dr. Roman Cholij, Trademark Attorney

 To register: seminars@israel-patents.co.il


Cosopt Patent Remains Dead – Teva to Produce a Generic Version of the Glaucoma Treatment

April 11, 2011


A U.K. appeals court has rejected an attempt bid by Merck & Co. Inc. to revive a European patent covering Cosopt, paving the way for Teva UK Ltd. to push forth a generic version of the glaucoma treatment.
Merck & Co., is the second-biggest U.S. drug company. Teva UK is a subsidiary of Israel’s Teva Pharmaceutical Industries, the world’s biggest maker of generic drugs.
Teva sued Merck three years ago claims the patent shouldn’t have been granted after Merck filed the application in 1992. The Appeal upheld a November 2009 ruling that Merck’s patent lacked novelty or inventiveness was correct because experts in the field would have found the development to be obvious.
COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
Glaucoma is a disease of the optic nerve which receives light-generated nerve impulses from the retina and transmits these to the brain, where we recognize those electrical signals as vision.
Glaucoma is characterized by a particular pattern of progressive damage to the optic nerve that generally begins with a subtle loss of side vision (peripheral vision). If glaucoma is not diagnosed and treated, it can progress to loss of central vision and blindness.


Follow

Get every new post delivered to your Inbox.

Join 90 other followers